At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Hyaluronidase +1 moredrug
Likely dose
Hyaluronidase 150 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Hyaluronidase Study
In Brief
A Phase 1 clinical trial evaluating Hyaluronidase and Control for Type 1 Diabetes Mellitus. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This research study examines the effect of hyaluronidase on the length of time of insulin infusion set wear. The aim of the study is to improve the length of time that an infusion set can be worn by infusing hyaluronidase directly into the insulin infusion site.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesUnited States
CollaboratorsUniversity of Colorado, Denver
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedJul 24, 2014
Enrollment StartJul 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.9 years ago
Interventions
Hyaluronidasedrug
150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
Controlother
No hyaluronidase administered into insulin infusion set.